Designed to inhibit DPP-4, the enzyme found to degrade GLP-1 (7-37), this drug, generically called sitagliptin, was developed at Merck by its first research team solely led by women
Data were generated and/or analysed by the Proteomics Resource Center (RRID: SCR_017797), Electron Microscopy Resource Center, Bioinformatics Resource Center, Fisher Drug Discovery Resource Center and the Flow Cytometry Resource Center at The Rockefeller University
Crugnola V, Lamperti C, et al
Monitor Progress: Take photos to track your skins progress over time
One of the main benefits is the noticeable reduction in cravings, which makes it easier to maintain smaller portions and avoid snacking between meals